Matt Bodenstein is a director in Sterne Kessler’s Biotechnology & Chemical Practice Group where he advises a diverse range of clients in the chemical, pharmaceutical, food science, material science, and biotechnology spaces. He has been recognized by his clients and peers as a leading patent strategist and is well-known for his thoughtful and creative approaches to obtaining business-critical patents.

Matt’s practice includes assisting clients with creating and managing strategic patent portfolios, managing complex and high priority patent prosecution (including “Track 1” applications), conducting and managing complex due diligence investigations in connection with potential investments, acquisitions, and licensing opportunities, and rendering freedom to operate, validity, and non-infringement opinions.

In addition to his focus on pure patent matters, Matt regularly helps clients negotiate term sheets, license agreements, and other strategic transactions.

Prior to joining Sterne Kessler, Matt was Intellectual Property Counsel for the former Medicis Pharmaceutical Corp., and an associate and patent agent in the IP Group of an AmLaw 100 law firm.

Before becoming a lawyer, Matt worked in the CNS Medical Chemistry group at Pfizer, Inc. and the Process Research and Development Group at Merck & Co., Inc.

Matt earned his J.D., cum laude, from Temple University Beasley School of Law, and his M.S. and B.A. degrees in Chemistry, from the University of Pennsylvania.

Outside of work, Matt can often be found walking his Great Pyrenees/hound mix, Ripley, relaxing with his family at a Nats or DC United game, or cranking away on his bike (look for him on Zwift!).

  • IAM Strategy 300, “Global Leaders Guide” (2023 – 2021)
  • IAM Strategy 300, “A Guide to the World’s Leading IP Strategists” (2023 – 2021)

  • J.D., Temple University Beasley School of Law, cum laude
  • M.S., Organic Chemistry, University of Pennsylvania
  • B.A., Chemistry, University of Pennsylvania

  • District of Columbia
  • Pennsylvania
  • U.S. District Court for the Eastern District of Pennsylvania
  • United States Patent & Trademark Office

Speaking Engagement

2023 Focus on Pharma

Washington, DC, April 14, 2023 8:30 AM - 6:00 PM EST

Speaking Engagement

2019 Global IP Strategy Conference

Washington, DC, March 15, 2019 12:00 AM - 11:59 PM EST

Related Resources

From Matthew S. Bodenstein

Press Release

September 28, 2023

Prestigious IAM Strategy 300 Features Five Sterne Kessler Attorneys in 2023 Guide

Sterne, Kessler, Goldstein & Fox

Press Release

December 19, 2022

Directors Bodenstein, Durkin, and Sterne Recognized as 2023 IAM Strategy 300 Global Leaders

Sterne, Kessler, Goldstein & Fox

Press Release

September 12, 2022

Directors Bodenstein, Durkin and Sterne Ranked Among Global IP Leaders in 2022 IAM Strategy 300

Sterne, Kessler, Goldstein & Fox

In the News

March 31, 2022

EU Unified Patent Court Spurs Delight and Fear for Experts

Law360

Press Release

January 17, 2022

Four Sterne Kessler Directors Featured in IAM Strategy 300 Global Leaders 2022 Guide

Sterne, Kessler, Goldstein & Fox

Press Release

August 31, 2021

Directors Bodenstein, Durkin, Ellison, and Sterne Ranked in 2021 IAM Strategy 300

Sterne, Kessler, Goldstein & Fox

Books and Chapters

October 1, 2019

U.S. Chemical Patent Law: A Practical Guide

Bloomberg Law Multiple Authors

Press Release

October 1, 2019

Sterne Kessler Attorneys Author U.S. Chemical Patent Law

Sterne, Kessler, Goldstein & Fox P.L.L.C Multiple Authors

Bylined Articles

February 1, 2019

Supreme Court Clarifies Applicability of ‘On-Sale’ Bar to Patented Inventions

Bloomberg Law Multiple Authors

In the News

January 30, 2019

Attorneys React to Teva’s High Court Win in ‘Secret’ Patent Sale Case

Westlaw Journal Multiple Authors

In the News

January 22, 2019

'On Sale' Ruling Shows Need For Earlier Patent Applications

Law360 Multiple Authors

In the News

April 28, 2017

Law360 Names Attys Who Moved Up The Firm Ranks in Q1

Multiple Authors

Press Release

January 16, 2017

Sterne, Kessler, Goldstein & Fox Elects Five New Directors

Multiple Authors